Acquires its portfolio of NLRP3 targeting drugs
You may also like
Novartis drops phase 2 radioligand therapy, but...
Indian generics maker Lupin seeds US spinout Kaveri...
Roche taps Foundation Medicine’s chief as new North...
‘There is always a first’: Why US biotech Axiom...
Genetic medicine luminaries launch new center for...
Agios says adios to sickle cell program over...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
